Clover Health Investments, Corp.
NASDAQ:CLOV · NASDAQ Global Select
+$0.17 today
Vol 7.06M · Avg 7.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.7%
avg 257890.5%
ROIC
-25.7%
avg 129827.6%
ROA
-15.8%
avg -45349.3%
Analysis
ROA is currently the strongest return metric at -15.8% versus its period average of -45349.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jamie L. Reynoso | Chief Executive Officer of Medicare Advantage | $1.47M | — | 57 | $2.84M | 0.55% |
Andrew Toy | Co-Founder, Chief Executive Officer & Director | $1.32M | — | 47 | $9.92M | 1.91% |
Conrad Wai | Chief Executive Officer of Counterpart Health | $1.21M | — | 45 | $1.39M | 0.27% |
Brady Priest | Chief Executive Officer of Clover Care Services | $1.20M | — | 50 | $2.04M | 0.39% |
Karen Soares | Chief Legal Officer, Senior VP & Corporate Secretary | $513,197.00 | — | 48 | $1.57M | 0.30% |
Peter J. Kuipers | Advisor | $367,213.00 | — | 54 | $5.76M | 1.11% |
Kumar Dharmarajan | Chief Medical Officer of Clover Assistant | — | — | 46 | — | — |
Vivek Garipalli | Co-Founder & Executive Chairman | — | — | 47 | $10.25M | 1.98% |
Wendy Richey | Chief Compliance Officer | — | — | — | — | — |
Joseph Frank Oldakowski | VP of Finance, Controller & Principal Accounting Officer | — | — | 43 | $299,067.00 | 0.06% |
Clay Thornton | Interim Chief Financial Officer | — | — | 36 | $1.22M | 0.23% |
Rachel Fish | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$1.07M
Sells
23
$3.02M
Net Sentiment
$1.96M
Net selling
Most Active
Reynoso Jamie L.
14 transactions
1–10 of 27
Analysis
Insiders reported 4 buys worth $1.07M and 23 sells worth $3.02M over the last 12 months. That adds up to net selling of $1.96M. Reynoso Jamie L. was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +33.4% | +20.3% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +33.4% over three years. Forward estimates point to Revenue at +20.3% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$5.34B
10x Genomics, Inc.
NASDAQ:TXG
$4.42B
LifeStance Health Group, Inc.
NASDAQ:LFST
$3.42B
National HealthCare Corporation
AMEX:NHC
$3.02B
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.76B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.63B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.22B
QuidelOrtho Corporation
NASDAQ:QDEL
$898.91M
Certara, Inc.
NASDAQ:CERT
$891.23M
BGM Group Ltd.
NASDAQ:BGM
$74.69M
Who manages CLOV?
Clover Health Investments, Corp. (CLOV) lists 12 active executives. The top listed executive is Kumar Dharmarajan, Chief Medical Officer of Clover Assistant.
Are CLOV insiders buying or selling?
Recent insider activity shows net selling of $37.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.